CoChat

Effects of Dose and Duration of Zinc Interventions on Risk Factors for Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis

Open access
Pompano, Laura M, Boy, Erick · 2021 · Advances in Nutrition

The DOI matches its Crossref record; 94 of the 99 references it cites were found in a registry or an index.

Abstract

No meta-analysis has examined the effect of dose and duration of zinc interventions on their impact on risk factors for type 2 diabetes (T2D) or cardiovascular disease (CVD). This study aimed first to compare the effects of zinc interventions dichotomized as low versus high dose (<25 mg/d and ≥25 mg/d, respectively) and short versus long duration (<12 wk and ≥12 wk, respectively) on risk factors for T2D and CVD. Second, it discusses the results from the low-dose and long-duration meta-analyses as a foundation for understanding what impact a zinc-biofortification intervention could have on these risk factors. The PubMed and Cochrane Review databases were searched through January 2020 for full-text, human studies providing zinc supplements (alone) at doses ≤75 mg/d and a placebo. Data on study and sample characteristics and several T2D and CVD risk factors were extracted. There were 1042 and 974 participants receiving zinc and placebo, respectively, from 27 studies. Low-dose zinc supplementation (<25 mg/d) significantly benefited fasting blood glucose, insulin resistance, triglycerides, total cholesterol, and LDL cholesterol. High-dose zinc supplementation (≥25 mg/d) benefited glycated hemoglobin and insulin resistance. Short-duration interventions (<12 wk) benefited fasting blood glucose, insulin resistance, and triglycerides, while long-duration studies (≥12 wk) benefited fasting blood glucose, triglycerides, and total and LDL cholesterol. Effect sizes for low-dose and long-duration interventions were of equal or greater magnitude to those from high-dose or short-duration interventions. Low-dose and long-duration zinc supplementation each improved more risk factors for T2D and CVD than high-dose and short-duration interventions, respectively. It is currently unknown whether low doses of zinc delivered over long durations via a biofortified crop would similarly impact these risk factors. However, this review suggests that low-dose, long-duration zinc intake from supplements, and potentially biofortification, can benefit risk factors for T2D and CVD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/advances/nmaa087

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 PRISMA flow chart for study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
FIGURE 1 PRISMA flow chart for study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.CC BY · PubMed Central
FIGURE 2 Risk-of-bias assessment by study and domain. Bias rankings were based on the Cochrane Review Risk of Bias tool and guidelines (51). Allocation concealment, allocation concealment (selection bias); Blinding: outcomes, blinding of outcome assessment (detection bias); Blinding: participants, blinding of participants and personnel (performance bias); Incomplete data, incomplete outcome data (attrition bias); Random Seq. Allocation, random-sequence allocation (selection bias); Selective reporting, selective reporting (reporting bias).
FIGURE 2 Risk-of-bias assessment by study and domain. Bias rankings were based on the Cochrane Review Risk of Bias tool and guidelines (51). Allocation concealment, allocation concealment (selection bias); Blinding: outcomes, blinding of outcome assessment (detection bias); Blinding: participants, blinding of participants and personnel (performance bias); Incomplete data, incomplete outcome data (attrition bias); Random Seq. Allocation, random-sequence allocation (selection bias); Selective reporting, selective reporting (reporting bias).CC BY · PubMed Central
FIGURE 3 Meta-analyses of the mean difference between zinc and placebo for fasting blood glucose, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 3 Meta-analyses of the mean difference between zinc and placebo for fasting blood glucose, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central
FIGURE 4 Meta-analyses of the mean difference between zinc and placebo for HbA1c, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. HbA1c, glycated hemoglobin; IV, inverse variance.
FIGURE 4 Meta-analyses of the mean difference between zinc and placebo for HbA1c, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. HbA1c, glycated hemoglobin; IV, inverse variance.CC BY · PubMed Central
FIGURE 5 Meta-analyses of the mean difference between zinc and placebo for HOMA-IR, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 5 Meta-analyses of the mean difference between zinc and placebo for HOMA-IR, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central
FIGURE 6 Meta-analyses of the mean difference between zinc and placebo for triglyceride concentration, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 6 Meta-analyses of the mean difference between zinc and placebo for triglyceride concentration, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central
FIGURE 7 Meta-analyses of the mean difference between zinc and placebo for total cholesterol, by dose and duration.(A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 7 Meta-analyses of the mean difference between zinc and placebo for total cholesterol, by dose and duration.(A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central
FIGURE 8 Meta-analyses of the mean difference between zinc and placebo for LDL cholesterol, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 8 Meta-analyses of the mean difference between zinc and placebo for LDL cholesterol, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central
FIGURE 9 Meta-analyses of the mean difference between zinc and placebo for HDL cholesterol, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.
FIGURE 9 Meta-analyses of the mean difference between zinc and placebo for HDL cholesterol, by dose and duration. (A) Studies providing low-dose supplementation, defined as <25 mg elemental Zn/d. (B) Studies providing high-dose supplementation, defined as ≥25 mg elemental Zn/d. (C) Studies providing short-duration supplementation, defined as <12 wk. (D) Studies providing long-duration supplementation, defined as ≥12 wk. IV, inverse variance.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. American Heart Association, 2019, Heart disease and stroke statistics—2019 at-a-glance heart disease, stroke and other cardiovascular diseases [Internet]
  2. Pachotikarn, 1985, Effect of oral zinc supplementation upon plasma lipids, blood pressure, and other variables in young adult white males, Nutr Rep Int, 32, 373
  3. Gómez-García, 2006, [Effect of oral zinc administration on insulin sensitivity, leptin and androgens in obese males.], Rev Med Chil, 134, 279
  4. Ranasinghe, 2018, Zinc supplementation in prediabetes: a randomized double-blind placebo-controlled clinical trial, J Diabetes, 10, 386, 10.1111/1753-0407.12621 · DOI · Paper page

Cited by

See all 97

Metadata

Authors
Pompano, L. M., & Boy, E.
Affiliations
International Food Policy Research Institute (US)
Corresponding author
Boy, Erick
Venue
Advances in Nutrition
Publisher
Elsevier BV
Published
2021-01
Volume
12
Issue
1
Pages
141-160
ISSN
  • 2156-5376 (ISSN-L)
  • 2161-8313
OpenAlex
W3045984165
Cited by
97
References
99
Citations by year
2026: 7 · 2025: 16 · 2024: 16 · 2023: 25 · 2022: 18 · 2021: 14
FWCI
1.78
Type
journal article
Language
en
Update notices
erratum (2021-05-01)
Open access
Licence
Locations
  • Advances in Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IFPRI E-brary (International Food Policy Research Institute) (submittedVersion, other-oa)
  • CGSPace A Repository of Agricultural Research Outputs (Consultative Group for International Agricultural Research) (submittedVersion, other-oa)
  • International Food Policy Research Institute (International Food Policy Research Institute) (submittedVersion, other-oa)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
  • Health Sciences › Nursing › Nutrition and Dietetics › Magnesium in Health and Disease
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Plant Micronutrient Interactions and Effects
Keywords
zinc supplementation, dose-response relationship, intervention duration, type 2 diabetes risk factors, cardiovascular risk factors, insulin resistance, fasting blood glucose, HbA1c, triglycerides, LDL cholesterol, total cholesterol, zinc biofortification, micronutrient supplementation
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Risk Factors, Zinc

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.